Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ravi Chhatrala

Gastroenterology Newport News, VA Medical Doctor

NPI 1033438544 CMS profile 1392270

11803 Jefferson Ave, Suite 230, Newport News, VA 23606

Open in the dashboard

General payments

$9,414

497 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ravi Chhatrala of Newport News, VA is reported in the CMS Open Payments database as having received $9,414 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,638 116
2024 General $2,027 95
2023 General $1,616 87
2022 General $608 35
2021 General $128 8
2020 General $384 22
2019 General $2,012 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ravi Chhatrala
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ravi Chhatrala were reported at $2,638. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ravi Chhatrala Gastroenterology median Middle half National median
2019 $2,012 $417 $126–$1,100 $163
2020 $384 $224 $74–$624 $114
2021 $128 $352 $106–$1,054 $132
2022 $608 $448 $129–$1,270 $149
2023 $1,616 $533 $150–$1,390 $160
2024 $2,027 $605 $160–$1,606 $164
2025 $2,638 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,689 141 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,323 79 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $992 53 payments
  4. Janssen Biotech, Inc. $899 44 payments
  5. Ardelyx, Inc. $387 19 payments
  6. Gilead Sciences, Inc. $282 10 payments
  7. Pfizer Inc. $241 11 payments
  8. Ferring Pharmaceuticals Inc. $233 6 payments
  9. Regeneron Healthcare Solutions, Inc. $217 9 payments
  10. Lilly USA, LLC $189 8 payments
  11. Other $1,961 117 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,349 494 payments
  2. Education $54 2 payments
  3. Consulting Fee $11 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $1,089 54 payments
  2. ENTYVIO $867 48 payments
  3. XIFAXAN $790 37 payments
  4. SKYRIZI Immunology $729 35 payments
  5. HUMIRA $696 42 payments
  6. LINZESS $607 42 payments
  7. TREMFYA $581 29 payments
  8. CREON $485 28 payments
  9. STELARA $443 16 payments
  10. SKYRIZI Immunology $439 19 payments
  11. Other $4,314 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

511

Median for Internal Medicine: 777

Drug cost

$56,590

Median for Internal Medicine: $73,373

Branded share of claims

13.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 36 $35,682
Mesalamine Generic 11 $5,236
Dexlansoprazole Dr Dexlansoprazole Brand 12 $3,723
Lubiprostone Generic 13 $2,347
Omeprazole Generic 137 $2,124
Vancomycin Hcl Generic 14 $1,984
Esomeprazole Magnesium Generic 31 $1,399
Pantoprazole Sodium Generic 96 $1,066
Dicyclomine Hcl Generic 36 $754
Loperamide Loperamide Hcl Brand 12 $527

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$203,186

Medicare's payments for the services billed

Medicare patients

674

Average age 75

Services billed

1,264

377 women, 297 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 28%
Diabetes 26%
Depression 23%
Chronic kidney disease 21%
Heart failure 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
$224 — —
ENTYVIO
$204 — —
RINVOQ
$188 — —
SKYRIZI
$162 — —
LINZESS
$152 36 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record